ESMO 2025: A Potential New Anthracycline-Free Neoadjuvant Regimen for Patients with High-Risk HER2-Positive Early Breast Cancer
The DESTINY-Breast11 trial showed that anthracycline-free T-DXd-THP improved response rates and safety compared with standard therapy in high-risk HER2-positive early breast cancer.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
